Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (>= 75) patients

Alkan, Ali; GÜÇ, ZEYNEP; Gurbuz, Mustafa; ozgun, Guliz; Degirmencioglu, Serkan; Dogan, Mutlu; AKIN TELLİ, TUĞBA; KESKİN, ÖZGE; Arslan, Cagatay; Bilgin, Burak; SEZGİN GÖKSU, SEMA; Demir, Hacer; Koksoy, Elif; Kostek, Osman; Erturk, Ismail; ŞAKALAR, Teoman; Yasar, Arzu; Turkkan, Gorkem; Kasim, Bu; KARAOĞLU, AZİZ; oksuzoglu, Berna; Yumuk, Fulden; ŞENDUR, MEHMET; COŞKUN, HASAN; ÇİÇİN, İRFAN; Karadurmu, Nuri; TANRIVERDİ, ÖZGÜR; AKBULUT, HAKAN; ÜRÜN, YÜKSEL

doi:10.31083/jomh.2021.041

Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (>= 75) patients

Copy For Citation

Alkan A., GÜÇ Z. G., Gurbuz M., ozgun G., Degirmencioglu S., Dogan M., ...More

JOURNAL OF MENS HEALTH, vol.17, pp.128-134, 2021 (SCI-Expanded)

Publication Type: Article / Article
Volume: 17
Publication Date: 2021
Doi Number: 10.31083/jomh.2021.041
Journal Name: JOURNAL OF MENS HEALTH
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.128-134
Keywords: Metastatic castration-resistant prostate cancer, Enzalutamide, Abiraterone Acetate, Elderly
Erciyes University Affiliated: No

Abstract

Introduction: The efficacy and tolerability of Enzalutamide and Abiraterone Acetate have been reported in elderly patients with metastatic castration resistant prostate cancer (mCRPC). However, there is no randomized study directly comparing antitumor effects between these 2 agents in geriatric patients. We aimed to evaluate the efficacy of Enzalutamide (ENZA) and Abiraterone Acetate (AA) as a first-line treatment of mCRPC in elderly patients.